Detalhe da pesquisa
1.
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
J Rheumatol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621793
2.
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Ann Rheum Dis
; 81(2): 206-213, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615638
3.
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
Rheumatology (Oxford)
; 60(7): 3209-3221, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33313898
4.
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Lancet
; 393(10188): 2303-2311, 2019 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31130260
5.
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 391(10139): 2503-2512, 2018 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29908669
6.
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Arterioscler Thromb Vasc Biol
; 34(6): 1298-306, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24743431
7.
Economic Burden among Patients with Vitiligo in the United States: A Retrospective Database Claims Study.
J Invest Dermatol
; 144(3): 540-546.e1, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37739338
8.
Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis.
Dermatol Ther (Heidelb)
; 13(10): 2265-2277, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37668899
9.
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
Cell Metab
; 3(6): 403-16, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16753576
10.
Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Clin Pharmacol Drug Dev
; 10(11): 1335-1344, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34109764
11.
Selective activation of PPARgamma in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance.
Am J Physiol Endocrinol Metab
; 298(1): E28-37, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19843873
12.
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
J Clin Pharmacol
; 60(2): 188-197, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31448433
13.
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
Arthritis Res Ther
; 22(1): 137, 2020 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32517782
14.
Quantitative measurements of corticosteroids in ex vivo samples using on-line SPE-LC/MS/MS.
J Chromatogr B Analyt Technol Biomed Life Sci
; 877(3): 303-10, 2009 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19119084
15.
Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
Clin Pharmacol Ther
; 106(6): 1319-1327, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31194885
16.
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
Arthritis Res Ther
; 21(1): 272, 2019 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31815649
17.
Gene expression analysis in rats treated with experimental acetyl-coenzyme A carboxylase inhibitors suggests interactions with the peroxisome proliferator-activated receptor alpha pathway.
J Pharmacol Exp Ther
; 324(2): 507-16, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18025247
18.
Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
Bioorg Med Chem Lett
; 18(15): 4298-302, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18632269
19.
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).
BMC Rheumatol
; 2: 23, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30886973
20.
4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
J Med Chem
; 50(21): 5090-102, 2007 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-17880056